Board of Directors & Leadership Team
The leadership team of ADRx has extensive knowledge in drug discovery and development at companies including Amgen, Genentech, and ICOS, and proven experience in leading successful drug development research efforts through commercialization resulting in novel therapeutics.
David Eisenberg, Ph.D. (Co-Founder, Chairman of Scientific Advisory Board) is a Professor of Chemistry and Biochemistry and Professor of Biological Chemistry at the University of California, Los Angeles, and Director of the UCLA-DOE Institute for Genomics and Proteomics. His expertise is in the amyloid state of proteins in disease. He received his undergraduate degree in biochemical sciences from Harvard College and his D.Phil. degree in theoretical chemistry from Oxford University. His postdoctoral research was on ice and water with Walter Kauzmann at Princeton and in protein crystallography with Richard Dickerson at California Institute of Technology. Dr. Eisenberg is an elected member of the National Academy of Sciences, the Institute of Medicine, the American Academy of Arts and Sciences, and the American Philosophical Society. He is an HHMI Investigator and Paul D. Boyer Professor of Molecular Biology as well as a recipient of the 2004 UCLA Seaborg Medal, the 2005 Harvard Westheimer Medal, and the 2008 Emily Gray Award from the Biophysical Society. Dr. Eisenberg has produced more than 400 scientific papers that have been cited by over 80,000 other scientific papers.
John B. Frank, J.D. (Chairman of Board of Directors) is Oaktree’s Vice Chairman and he works closely with Howard Marks, Bruce Karsh and Jay Wintrob in managing the firm. Mr. Frank joined in 2001 as General Counsel and was named Oaktree’s Managing Principal in early 2006, a position that he held for about nine years. As Managing Principal, Mr. Frank was the firm’s principal executive officer and responsible for all aspects of the firm’s management. Prior to joining Oaktree, Mr. Frank was a partner of the Los Angeles law firm of Munger, Tolles & Olson LLP where he managed a number of notable merger and acquisition transactions.
Madhu Balachandran (Member of the Board of Directors) was Executive Vice President, Operations of Amgen Inc., a global biotechnology company, from August 2012 until July 2016 and retired as an Executive Vice President in January 2017.Mr. Balachandran joined Amgen in 1997 as Associate Director, Engineering. He became Director, Engineering in 1998, and, from 1999 to 2001, he held the position of Senior Director, Engineering and Operations Services before moving to the position of Vice President, Information Systems from 2001 to 2002. Thereafter, Mr. Balachandran was Vice President, Puerto Rico Operations from May 2002 to February 2007. From February 2007 to October 2007, Mr. Balachandran was Vice President, Site Operations, and, from October 2007 to August 2012, he held the position of Senior Vice President, Manufacturing. Prior to his tenure at Amgen, Mr. Balachandran held leadership positions at Copley Pharmaceuticals, now a part of Teva Pharmaceuticals Industries Ltd., and Burroughs Welcome Company, a predecessor through mergers of GlaxoSmithKline plc. He has served as a director of Stevanato Group since September 2018, Catalant, Inc. since May 2017 and as a director of uniQure NV since September 2017. Mr. Balachandran holds a Bachelor of Technology degree in Chemical Engineering from The Indian Institute of Technology in Bombay, a Master of Science degree in Chemical Engineering from The State University of New York at Buffalo, and an MBA from East Carolina University.
James Treanor, Ph.D. (Member of Board of Directors) was CEO of ADRx from 2015-2019. He is a Ph.D. scientist with 25 years of academic and industrial experience investigating drug targets and drugs. He worked 18 years at Amgen where he last served as Scientific Executive Director after two years with Genentech in the Bay Area. At Amgen, James led research in neurodegeneration and neuropsychiatry and helped to develop and support the progression of nine small molecule and two biologics clinical candidates through regulatory submissions. He worked at Amgen on the recently approved migraine therapy, Aimovig, and has focused on developing therapeutics for pain, neurodegeneration, Alzheimer’s disease, Parkinson’s disease, multiple sclerosis and neuropsychiatric disorders. James has managed scientific staffs of 36 people.
Christine Brennan, Ph.D. (Member of Board of Directors) has over 15 years in the life-science industry including business development, corporate strategy and venture investing. She is currently Partner at MRLV and on the boards of Entrada Therapeutics, PAQ Therapeutics, Tallac Therapeutics and Therini Bio. She was previously on the boards of Alector [NASDAQ:ALEC] and Translate Bio [NASDAQ:TBIO].Prior to becoming part of the MRLV team, she was Principal at the Novartis Venture Fund from 2013-2017 where she was on the board of Altimmune [NASDAQ:ALT] and an observer on the boards of a number of companies including ROX Medical, lnnocrin Pharmaceuticals, Viamet Pharmaceuticals and Quartet Medicine. Prior to Novartis Venture Fund, she was Chief Business Officer at Vitae Pharmaceuticals from 2010-2013. She also held positions in business development and marketing at small and mid-size biopharmaceutical companies. Christine received her Ph.D. in neuroscience from Dartmouth Medical School and post-doctoral research in developmental neurobiology from the National Institutes of Health.
Marcin Apostol, Ph.D (President) was founding scientist at ADRx and has spent much of his scientific career researching protein aggregation. He has a Ph.D. in structural biology from UCLA and did post doctoral training in biophysics at Case Western Reserve University and the Cleveland Clinic. Marcin has authored 20 works in top journals and 4 patents, many on the topic of protein structure and the molecular determinants of aggregation.
Scientific Advisory Board - Dr. David Eisenberg, Chair
The Scientific Advisory Board is a team of thought leaders from the industry and academia.
Tom Boone, M.A. retired from Amgen in 2009 as VP, Protein Sciences overseeing a biologics R&D team of over 300 researchers across five sites. Tom currently consults or acts as an advisor for more than 10 companies and owns his own company developing biologics for companion animals. During his 28-years with Amgen, he cloned and sequenced genes including G-CSF (Neupogen); directed the development of processes implemented at Amgen, including the Neupogen process. He headed the expression, purification, and characterization groups (Protein Science Group) within Amgen's research group.
Ken Kosik, M.D. is the Co-Director of UCSB Neuroscience Research Institute and Founder of CFIT, now a program of Santa Barbara Cottage Hospital. He received his M.D. degree from the Medical College of Pennsylvania, completed a neurology residency from Tufts New England Medical Center, and held various appointments at the Harvard Medical School. In the fall of 2004 he assumed the co-directorship of the Neuroscience Research Institute and the Harriman Chair at the University of California Santa Barbara. He has received multiple awards, including a Whitaker Health Sciences Award from Massachusetts Institute of Technology, the Derek Denny-Brown Neurological Scholar Award from the American Neurological Association, the Zenith Award from the Alzheimer’s Association, and a NASA Group Achievement Award.
Lyn Frumkin, M.D./Ph.D. consults on biotechnology and life sciences investment opportunities for start-up and early stage biotechnology companies and venture capital firms. Lyn previously worked at the biotechnology companies Amgen, Inc. and ICOS Corp., where he provided broad expertise, including leading clinical teams conducting global development programs across multiple therapeutic indications and negotiating regulatory strategy for successful approval of pivotal trials and programs in North America, Europe, and Japan. Lyn received a combined MD-PhD (Behavioral Medicine/Neuroscience) with Honors from the University of Washington.
Nancy Stagliano, Ph.D. is an accomplished serial biotechnology entrepreneur and has successfully launched and/or exited three biotech companies: CytomX Therapeutics (CTMX), iPierian and, most recently, True North Therapeutics. Before moving to California, Nancy had an eight-year tenure at Millennium Pharmaceuticals. She obtained her doctor of philosophy degree in neuroscience from the University of Miami, Miller School of Medicine, in Miami.
In Memorium: Gary Wilcox
ADRx, Inc. announces with deep sadness the sudden death of Dr. Gary Wilcox, Chairman and Co-Founder on Tuesday May 25. The Board of Directors and Staff of ADRx extend deep sympathy to the Wilcox family on their loss. Gary was a mainstay of ADRx, and was admired by all for his inspired leadership and friendship, and for his life-long dedication to improving human health through fundamental science and biotechnology. The work that Gary inspired at ADRx continues to make progress with current board member, John Frank, stepping in as Chairman of the Board of Directors.